Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2020 16:01 ET | Source: Retrophin, Inc.

Retrophin Reports Second Quarter 2020 Financial Results

Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021 Net product sales increased...